Yoko Nakanishi
Papers
1
Total Citations
12
H-Index
1
About
Yoko Nakanishi has made foundational contributions to the molecular pathology of breast cancer, particularly in refining the assessment of HER2 status—a critical biomarker for targeted therapy with trastuzumab (Herceptin). Her most cited work, a 2004 study employing laser-assisted microdissection, directly compared HER2 mRNA amplification with standard immunohistochemistry in human breast cancer. This research addressed a key clinical challenge: ensuring that only patients with true HER2 overexpression (score 3+) receive the drug, thereby optimizing prognosis. By demonstrating a strong correlation between protein expression and mRNA amplification, Nakanishi’s work helped validate more precise molecular techniques for patient stratification. With 12 citations, this study has informed subsequent guidelines for HER2 testing and precision oncology. Her research bridges the gap between histopathology and molecular diagnostics, underscoring her role in advancing personalized treatment for breast cancer patients. Nakanishi’s meticulous approach continues to influence how clinicians and researchers evaluate biomarker reliability, making her a notable figure in translational cancer pathology.
Research Focus
Key Achievements
Top Papers
- 1